Raymond James Resumes Sarepta Therapeutics (SRPT) at Outperform
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/29/2026
- S&P 500 flat as higher bond yields counter tech optimism
- Anthropic prospectus shows $2T IPO ambition, warns of AI 'existential risk'
- Risk appetite remains concentrated in large-cap stocks, Citi says
- Netflix stock: Deutsche Bank gets bullish as valuation leaves room to run
- CarMax shares rise over 2% on strong earnings and revenue beat
- Salesforce agrees to acquire AI research platform Listen Labs
- Workday cuts 2.5% of workforce, revises GAAP margin outlook
- Bloom Energy shares fall on Oracle project halt
- Exclusive-Activist Jana pushes Fiserv to accelerate cost cuts and tap Palantir
- Stocks fall as higher oil prices, Treasury yields weigh
Barclays Reiterates Overweight Rating on Sarepta Therapeutics (SRPT)
October 11, 2024 5:56 AM EDTBarclays analyst Gena Wang reiterated an Overweight rating and $203.00 price target on Sarepta Therapeutics (NASDAQ: SRPT).
The analyst comments "Key takeaways. At WMS 2024, SRPT late breaking presentation for Elevidys long-term data from Ph1-3 studies (Study 101, 102, 103, and EMBARK) showed relatively stable left ventricular... More
